查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093447

早產和胎膜早破 (PROM) 檢測市場－2026-2032 年全球市場預測

Preterm Birth & PROM Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，早產和胎膜早破 (PROM) 檢測市場將成長至 21.4 億美元，複合年成長率為 5.62%。

主要市場統計數據
基準年 2025 14.6億美元
預計年份：2026年 15.4億美元
預測年份 2032 21.4億美元
複合年成長率 (%) 5.62%

早產和胎膜早破（PROM）檢測在母嬰風險管理、降低新生兒發病率和循證產科分診中發揮核心作用。世界衛生組織（WHO）將早產定義為懷孕37週前分娩，早產仍是五歲以下兒童死亡的主要原因之一。胎膜早破（PROM）和胎膜早破（PPROM）會增加羊水感染、胎盤併發症、臍帶受壓和早產的風險。隨著醫療系統日益重視及時診斷，胎膜早破檢測擴大與臨床評估、超音波、胎兒監護、子宮頸評估和實驗室指標結合使用，以鑑別真正的羊膜破裂與生理性分泌物、尿失禁或出血等診斷不確定性。早產和羊膜破裂檢測的臨床價值在以下方面最為顯著：有助於快速決策，例如住院治療、產前皮質類固醇給藥、必要時使用硫酸鎂進行胎兒神經保護、臨床適宜時使用抗生素、轉診至更高級的新生兒護理機構以及分娩時機的選擇。這種需求的產生源於人們對高風險妊娠管理的認知不斷提高、產前保健範圍的擴大、床邊診斷的廣泛應用以及減少不必要的住院和乾預措施的迫切需求。監管條件、報銷政策、感染預防方案以及各地區在獲得專業產科和新生兒護理服務方面的差異也會影響這一現狀。對於醫療保健領導者而言，策略重點並非僅僅是引入檢測方法，而是要整合準確、快速且與工作流程相符的診斷流程，以改善母嬰結局，同時支持合理使用抗生素和資源高效的產科護理。

早產和胎膜早破 (PROM) 檢測領域的變革性變化。

目前，早產和胎膜早破（PROM）的檢測方式正經歷變革，從基於症狀的評估轉向客觀、規範的診斷，以便在分流、產科急診和門診快速實施。傳統的評估方法，例如無菌窺陰器檢查、羊水混合檢測、硝嗪試驗和羊齒狀結晶法，仍然具有臨床應用價值，但其準確性會受到精液、血液、感染疾病、潤滑劑以及不同操作者之間差異的影響。這促使人們加速採用基於生物標記的檢測方法（例如檢測羊水相關蛋白）以及多方面綜合方法（例如將診斷結果與懷孕週數、孕婦感染狀況、胎兒健康狀況和子宮頸觀察相結合）。另一個重大轉變是，人們越來越重視風險分層，而不是僅僅基於單一檢測結果進行決策。醫療系統正日益將胎膜早破（PROM）檢測與早產風險評估、子宮頸長度測量、胎兒纖連蛋白及其他必要生化指標的測量以及針對早產風險的標準化護理方案相結合。數位化病歷、電子分流流程和品質改善計畫也在減少醫療服務差異，尤其是在分娩量大的醫療機構。同時，解決孕產婦健康差異已成為關鍵問題。在產前保健、檢測基礎設施和新生兒重症監護資源有限的國家，可預防的不良妊娠結局負擔更重，因此，經濟實惠、便捷可靠的胎膜早破檢測尤為重要。因此，最顯著的變化體現在操作層面。診斷正從獨立的臨床工具轉變為母嬰安全體系的組成部分。

人工智慧對早產和胎膜早破（PROM）檢測的累積影響

人工智慧正逐漸影響早產和胎膜早破（PROM）篩檢，其角色並非在於作為獨立的診斷工具，而是透過風險預測、工作流程最佳化和臨床決策支援來實現。數據驅動的臨床實踐日益認知到，早產是多因素的，涉及既往產科史、子宮頸長度、感染疾病、發炎、孕婦合併症、多胎妊娠、社會經濟因素和環境暴露等。人工智慧模型可以分析結構化和非結構化電子健康記錄，幫助識別可能需要密切後續觀察、早期轉診或針對性干預的患者。然而，在廣泛應用之前，臨床有效性檢驗、偏差評估和區域校準仍然至關重要。在與胎膜早破相關的護理中，人工智慧可以透過將症狀表現、實驗室結果、孕週、超音波觀察、生命徵象、實驗室指標和胎兒狀況整合到標準化的風險評估路徑中來輔助分流。人工智慧還可以透過預測產科觀察床位需求、新生兒加護病房容量、皮質類固醇使用和轉診需求，提高營運效率。人工智慧的累積效應可能在其作為實證方案的輔助層而非取代臨床醫師判斷時最為顯著。關鍵的安全措施包括：透明地報告模型效能、使用代表性的訓練資料集、實施保護隱私的資料管治、持續監測人口統計偏差以及明確臨床決策的課責。在醫療體系完善的環境中，人工智慧可以提高預測準確性並減少不必要的住院。在資源匱乏的環境中，精心設計的數位化工具，輔以培訓和通訊基礎設施，可以在將專業知識擴展到第一線孕產婦護理方面發揮作用。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區由於出生人口眾多、產前保健服務覆蓋範圍不均以及都市區三級產科醫療服務水平存在顯著差異，面臨著沉重的孕產婦和新生兒健康負擔。該地區各國正在加強產前篩檢、轉診系統和醫療機構分娩準備工作，因此迫切需要快速胎膜早破（PROM）檢測，以便指導適當的轉診和乾預措施。北美地區的特點是擁有先進的產科分診系統、積極應用床邊診斷、完善的新生兒重症監護網路，並高度重視基於指南的胎膜早破和早產風險管理。在該地區，診斷準確性、與電子健康記錄的整合、與保險報銷系統的兼容性以及減少早產結局中種族、地域和社會經濟差異的努力，都在影響著這項檢測的推廣應用。在拉丁美洲，產前保健品質和產科專家的可及性仍然參差不齊，胎膜早破（PROM）檢測被視為提高分診一致性的關鍵，尤其是在服務於地域分散人口的公共醫療體系中。在歐洲，優勢包括結構化的孕產婦保健路徑、高比例的熟練助產士接生以及對體外診斷醫療設備的嚴格監管，這些都促使人們更加重視標準化方案、合理使用抗生素以及跨境證據的協調統一。在中東，由於醫院基礎設施、高危險妊娠服務以及國家衛生現代化計畫的投入，對母胎醫學能力的需求日益成長，胎膜早破檢測也越來越被視為應對更廣泛的產科急症的一部分。在非洲，許多地區仍面臨最嚴峻的醫療服務可近性挑戰，包括熟練醫護人員短缺、診斷基礎設施不足以及新生兒重症監護能力不足。因此，經濟實惠且可靠的胎膜早破檢測，如果能與感染控制、轉診系統以及基本的產科和新生兒急救相結合，將具有極其重要的公共衛生價值。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東南亞國協，孕產婦和新生兒健康受到重視，這體現在擴大產前保健範圍、改善醫院分娩服務以及開展公共衛生計畫以預防新生兒併發症。因此，胎膜早破（PROM）檢測對於在公立和私立混合醫療體系中及時分診至關重要。海灣合作理事會（GCC）國家正大力投資於先進的醫院基礎設施、專業的婦幼保健服務和數位化醫療轉型，支持將快速產科診斷納入高風險懷孕的高級急診護理路徑。歐盟在診斷品質、臨床證據、資料保護和病人安全方面提供高度監管的環境，有助於制定標準化的胎膜早破檢測方案，並對不同醫療系統的檢測效能進行仔細評估。在金磚國家，孕產婦健康狀況差異很大，從高度發展的都市區三級醫療中心到服務不足的農村醫療網路，不一而足。這些國家通用的需求是獲得擴充性且經濟實惠的診斷服務，以減少羊膜破裂​​的識別延遲，並控制早產風險。由於七國集團（G7）國家通常擁有成熟的新生兒護理體系、完善的產科指南以及先進的保險報銷和採購流程，因此關於胎膜早破（PROM）檢測的決策往往側重於臨床效用、工作流程效率、減少假陽性以及提高醫療公平性。北約成員國包括多個高所得和中高收入國家的醫療體系，這些體系強調緊急準備、供應鏈韌性、數位化互通性和實證醫學。在這些體系中，胎膜早破檢測日益被視為建構具有韌性的孕產婦保健基礎設施的重要組成部分，即使在公共衛生緊急事件、移民壓力和勞動力短缺的情況下，也必須保持其可靠性。

對早產和胎膜早破 (PROM) 檢測主要市場中的關鍵國家進行深入分析。

與許多其他高所得國家相比，美國的早產負擔明顯更高，種族、收入、地區因素以及產前保健的可近性等因素導致了這種差異。因此，準確的胎膜早破（PROM）檢測在產科分診和減少不必要的干預措施中發揮著至關重要的作用。加拿大重視全民健保、在地化的周產期保健和循證的母胎轉診系統，支持在廣大區域內互聯互通的醫療路徑中使用胎膜早破診斷。墨西哥和巴西面臨公立和私立產科醫療體系並存以及地區差異的局面，快速且經濟的胎膜早破檢測有助於更早地識別風險並做出更一致的轉診決策。在英國，胎膜早破檢測與疑似羊膜破裂的標準化管理之間已建立了緊密的聯繫，這得益於國家臨床指南、結構化的產科診療路徑和品質改進項目。德國、法國、義大利和西班牙擁有完善的產科和新生兒醫療保健體系，診斷方法的採用受到證據品質、保險報銷、感染控制標準和醫院採購慣例的影響。俄羅斯幅員遼闊，周產期服務覆蓋範圍不均，因此，擴充性的診斷方法對於加強區域層面的產科護理至關重要。中國和印度出生率高，且高度重視孕產婦和新生兒結局，因此迫切需要可靠的檢測方法，這些方法應適用於從現代化都市區醫院到資源匱乏地區的所有環境。日本、澳洲和韓國擁有先進的周產期醫療保健體系，孕婦族群老化嚴重，且對診斷準確性要求很高，因此，這些國家認為胎膜早破（PROM）檢測在管理高風險妊娠、評估早產風險和製定新生兒護理策略方面發揮著至關重要的作用。

為早產和胎膜早破 (PROM) 檢測領域的領導者提供實用建議。

產業領導者應優先考慮經臨床檢驗（PROM）檢測解決方案，這些方案需在真實臨床環境中展現出可靠性，包括血液污染、感染疾病、孕週差異以及不同患者群體等情況。產品開發應著重於快速報告結果、易用性、最低訓練要求、清晰的結果解讀以及與產科分診流程的兼容性。為促進推廣應用，相關人員應致力於建立將檢測與有意義的臨床結果聯繫起來的記錄，例如降低診斷不確定性、最佳化住院治療、合理使用皮質類固醇和抗生素、及時轉診以及減少不必要的干預。應儘早制定監管和品管策略，包括可靠的分析檢驗、臨床性能數據、上市後監測以及遵守不斷變化的體外診斷醫療設備法規。醫療系統應優先將PROM檢測整合到標準化的早產和胎膜早破臨床流程中，而不是單獨使用此檢測方法。培訓計畫應確保嚴格遵守正確的檢體採集、結果解讀、記錄和升級流程。與公共衛生機構、產科網路和專業協會合作可以提高方案依從性和公平獲取醫療服務的機會。在資源有限的環境下，領導者應優先考慮可負擔性、供應穩定性、耐溫性和分散式可用性。在任何環境下，只要隱私、知情同意和偏見管理得到保障，將資料與電子健康記錄和人工智慧臨床資料集整合就能創造長期價值。

早產和胎膜早破（PROM）檢測的調查方法

本執行摘要基於實證的二手研究和臨床知識整合，並參考了公共衛生、監管和醫療保健領域的權威資訊來源。研究途徑著重於世界衛生組織、各國公共衛生機構、同行評審的婦產科文獻、臨床實踐指南、檢驗法律規範以及婦幼保健政策資源的已驗證資訊。調查方法不包括市場規模估算、收入估算、市場佔有率計算和預測。證據評估涉及早產、胎膜早破 (PROM)、胎膜早破 (PPROM)、診斷測試性能、產科分診、母嬰結局、區域醫療保健系統的準備情況以及推廣應用障礙。透過比較醫療保健基礎設施的成熟度、產前保健的可及性、新生兒醫療服務接收能力、監管嚴格程度、公共衛生優先事項以及已記錄的孕產婦健康差異，得出區域、群體和國家層面的具體見解。分析還檢視了診斷測試在產科急診護理、轉診決策、合理使用抗生素和新生兒護理系統中的實際作用。本研究從臨床決策支援、預測分析、資料管治和實施安全性等角度評估了人工智慧相關的洞見，尤其著重於檢驗和偏差緩解。此調查方法旨在幫助相關人員了解早產和胎膜早破（PROM）檢測的演變，而無需依賴推測性的商業性預測，從而提供一個最佳化且具有臨床依據的觀點。

結論：透過改進胎膜早破檢測，改善了母嬰結局。

早產和胎膜早破 (PROM) 檢測在現代母嬰保健中日益重要，因為它們有助於臨床醫生在診斷不確定性可能影響母嬰結局的情況下，及時做出基於循證醫學的決策。最大的機會在於將準確的 PROM 診斷整合到標準化的分流流程、高風險妊娠路徑、轉診網路和數位醫療系統中。不同地區的需求差異顯著。高所得國家的醫療系統優先考慮準確性、工作流程效率、公平性和合規性，而資源匱乏的環境則需要經濟實惠、可靠且分散的檢測，以支持安全轉診和感染預防。人工智慧 (AI) 可以輔助預測早產風險並改善營運規劃，但其價值取決於檢驗的模型、代表性的資料集和負責任的臨床管治。對於產業領導者而言，成功的關鍵在於臨床可靠性、易用性、符合監管要求以及能夠在實際產科工作流程中展現可操作的價值。隨著孕產婦健康系統繼續優先考慮減少可預防的新生兒發病率和死亡率，胎膜早破檢測仍將是改善妊娠結局、最佳化醫療保健服務和支持全球更安全分娩的更廣泛策略中的重要診斷工具。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：早產和胎膜早破（PROM）檢測市場：依檢測類別分類

  • 早產檢查
  • 胎膜早破檢查

第8章：早產和胎膜早破（PROM）檢測市場：依技術分類

  • 免疫檢測
  • 分子診斷
  • 醫學影像技術
  • 基於感測器的監測

第9章：早產和胎膜早破（PROM）檢測市場：依檢測模式分類

  • 即時偵測 (POC)
  • 檢查室檢測
  • 連續監測系統

第10章：早產和胎膜早破（PROM）檢測市場：依產品類型分類

  • 診斷試劑盒
  • 儀器/分析儀
  • 消耗品
  • 軟體和演算法

第11章：早產和胎膜早破（PROM）檢測市場：依最終用戶分類

  • 門診治療
  • 診斷檢查室
  • 醫院和診所
  • 研究機構

第12章：早產和胎膜早破（PROM）檢測市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：早產和胎膜早破（PROM）檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：早產和胎膜早破（PROM）檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Arkray, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biosynex SA
  • CooperSurgical, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Ferring Pharmaceuticals A/S
  • Hologic Gen-Probe Incorporated
  • Laborie Medical Technologies Corp.
  • Medix Biochemica Oy
  • Metabolomic Diagnostics Ltd
  • NX Prenatal Diagnostics Ltd
  • Ortho Clinical Diagnostics Holdings plc
  • Panache HealthNeeds Pvt Ltd
  • PerkinElmer, Inc.
  • Progyny, Inc.
  • QIAGEN NV
  • Sera Prognostics Europe BV
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Toda Pharma
Product Code: MRR-42653751E7E1

The Preterm Birth & PROM Testing Market is projected to grow by USD 2.14 billion at a CAGR of 5.62% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.46 billion
Estimated Year [2026] USD 1.54 billion
Forecast Year [2032] USD 2.14 billion
CAGR (%) 5.62%

Preterm birth and premature rupture of membranes (PROM) testing sit at the center of maternal-fetal risk management, neonatal morbidity reduction, and evidence-based obstetric triage. Preterm birth, defined by the World Health Organization as birth before 37 completed weeks of gestation, remains a leading cause of death among children under five, while PROM and preterm PROM (PPROM) increase the risk of intra-amniotic infection, placental complications, cord compression, and early delivery. As health systems prioritize timely diagnosis, PROM testing is increasingly used alongside clinical assessment, ultrasound, fetal monitoring, cervical evaluation, and laboratory markers to distinguish true membrane rupture from physiologic discharge, urinary leakage, or bleeding-related diagnostic uncertainty. The clinical value of preterm birth and PROM testing is strongest when it supports faster decision-making on hospitalization, antenatal corticosteroid administration, magnesium sulfate for fetal neuroprotection when indicated, antibiotics when clinically appropriate, transfer to higher-level neonatal care, and delivery timing. Demand is shaped by rising awareness of high-risk pregnancy management, expanding antenatal care coverage, increasing use of point-of-care diagnostics, and the need to reduce unnecessary admissions and interventions. The landscape is also influenced by variations in regulatory pathways, reimbursement policies, infection prevention protocols, and access to skilled obstetric and neonatal services. For healthcare leaders, the strategic priority is not simply test adoption but the integration of accurate, rapid, and workflow-compatible diagnostic pathways that improve maternal and neonatal outcomes while supporting antimicrobial stewardship and resource-efficient obstetric care.

Transformative Shifts in the Preterm Birth and PROM Testing Landscape

The preterm birth and PROM testing landscape is being reshaped by a shift from symptom-based evaluation toward objective, protocol-driven diagnostics that can be performed rapidly in triage, emergency obstetric units, and outpatient settings. Traditional assessment methods such as sterile speculum examination, pooling, nitrazine testing, and ferning remain clinically relevant, but their performance can be affected by semen, blood, infection, lubricants, and examiner variability. This has accelerated the use of biomarker-based tests that detect proteins associated with amniotic fluid, as well as combined approaches that align diagnostic results with gestational age, maternal infection status, fetal wellbeing, and cervical findings. Another major transformation is the growing focus on risk stratification rather than single-test decision-making. Health systems are increasingly linking PROM testing with preterm labor assessment, cervical length measurement, fetal fibronectin or other biochemical markers where appropriate, and standardized care bundles for threatened preterm birth. Digital documentation, electronic triage pathways, and quality improvement programs are also reducing variation in care, particularly in facilities with high delivery volumes. At the same time, maternal health equity has become a defining theme. Countries with limited access to prenatal care, laboratory infrastructure, and neonatal intensive care face a higher burden of preventable adverse outcomes, making affordable, easy-to-use, and reliable PROM testing especially important. The most significant shift is therefore operational: diagnostics are moving from isolated clinical tools to embedded components of maternal-fetal safety systems.

Cumulative Impact of Artificial Intelligence on Preterm Birth and PROM Testing

Artificial intelligence is beginning to influence preterm birth and PROM testing through risk prediction, workflow optimization, and clinical decision support rather than through standalone diagnosis. Data-backed clinical practice increasingly recognizes that preterm birth is multifactorial, involving prior obstetric history, cervical length, infection, inflammation, maternal comorbidities, multiple gestation, socioeconomic factors, and environmental exposures. AI-enabled models can help analyze structured and unstructured electronic health records to identify patients who may require closer surveillance, earlier referral, or targeted intervention; however, clinical validation, bias assessment, and local calibration remain essential before broad deployment. In PROM-related care, AI can support triage by integrating symptom presentation, test results, gestational age, ultrasound findings, vital signs, laboratory markers, and fetal status into standardized risk pathways. It can also improve operational efficiency by predicting demand for obstetric observation beds, neonatal intensive care capacity, corticosteroid use, and transfer requirements. The cumulative impact is likely to be strongest where AI is implemented as an assistive layer within evidence-based protocols, not as a replacement for clinician judgment. Key safeguards include transparent model performance reporting, representative training datasets, privacy-preserving data governance, continuous monitoring for demographic bias, and clear accountability for clinical decisions. In mature settings, AI may enhance predictive accuracy and reduce avoidable admissions; in resource-constrained settings, carefully designed digital tools may extend specialist expertise to frontline maternal care when supported by training and connectivity.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific carries a substantial maternal and neonatal health burden due to large birth cohorts, heterogeneous prenatal care access, and wide differences in tertiary obstetric capacity between urban and rural areas. Countries across the region are strengthening antenatal screening, referral systems, and facility-based birth preparedness, creating a practical need for rapid PROM testing that can guide timely transfer and intervention. North America is characterized by advanced obstetric triage infrastructure, high use of point-of-care diagnostics, established neonatal intensive care networks, and strong emphasis on guideline-driven management of PPROM and threatened preterm labor. In this region, adoption is shaped by diagnostic accuracy, integration with electronic health records, reimbursement alignment, and efforts to reduce racial, geographic, and socioeconomic disparities in preterm birth outcomes. Latin America faces persistent variability in prenatal care quality and access to specialist obstetric services, making PROM testing relevant for improving triage consistency, particularly in public health systems serving geographically dispersed populations. Europe benefits from structured maternal care pathways, high rates of skilled birth attendance, and strong regulatory scrutiny for in vitro diagnostics, with increasing attention to standardized protocols, antimicrobial stewardship, and cross-border evidence harmonization. The Middle East shows rising demand for maternal-fetal medicine capabilities, driven by investment in hospital infrastructure, high-risk pregnancy services, and national health modernization programs, while PROM testing is increasingly positioned within broader obstetric emergency preparedness. Africa continues to face the highest access challenges, including shortages of skilled providers, diagnostic infrastructure, and neonatal intensive care capacity in many areas; therefore, affordable and robust PROM testing has particular public health value when linked to infection prevention, referral pathways, and basic emergency obstetric and newborn care.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are prioritizing maternal and newborn health through expanded antenatal care coverage, hospital delivery access, and public health programs that address preventable neonatal complications, making PROM testing important for timely triage across mixed public-private healthcare systems. The GCC has invested heavily in advanced hospital infrastructure, specialized women's health services, and digital health transformation, supporting the integration of rapid obstetric diagnostics into high-acuity care pathways for high-risk pregnancies. The European Union provides a highly regulated environment for diagnostic quality, clinical evidence, data protection, and patient safety, which encourages standardized PROM testing protocols and careful evaluation of test performance across diverse healthcare systems. BRICS countries represent a broad range of maternal health realities, from highly advanced urban tertiary centers to underserved rural networks; their common need is scalable, cost-conscious diagnostic access that can reduce delays in identifying membrane rupture and managing preterm birth risk. G7 countries typically have mature neonatal care systems, established obstetric guidelines, and sophisticated reimbursement and procurement processes, so decisions around PROM testing often focus on clinical utility, workflow efficiency, false-positive reduction, and health equity improvement. NATO member countries overlap with several high-income and upper-middle-income health systems that emphasize readiness, supply chain resilience, digital interoperability, and evidence-based care; within these systems, PROM testing is increasingly viewed as part of resilient maternal healthcare infrastructure that must remain reliable during public health emergencies, migration pressures, and workforce constraints.

Key Country Insights Across Major Preterm Birth and PROM Testing Markets

The United States has a significant preterm birth burden compared with many other high-income countries, with documented disparities by race, income, geography, and access to prenatal care, making accurate PROM testing central to obstetric triage and unnecessary intervention reduction. Canada emphasizes universal healthcare access, regionalized perinatal care, and evidence-based maternal-fetal referral systems, supporting the use of PROM diagnostics in coordinated care pathways across large geographies. Mexico and Brazil face mixed public-private maternal care environments and regional disparities, where rapid and affordable PROM testing can support earlier risk identification and more consistent referral decisions. The United Kingdom relies on national clinical guidance, structured maternity pathways, and quality improvement programs, creating strong alignment between PROM testing and standardized management of suspected membrane rupture. Germany, France, Italy, and Spain have well-developed obstetric and neonatal systems, where diagnostic adoption is influenced by evidence quality, reimbursement, infection control standards, and hospital procurement practices. Russia's large geography and uneven access to specialist perinatal services make scalable diagnostics relevant for strengthening regional maternity care. China and India, with large birth populations and major policy focus on maternal and newborn outcomes, show strong need for reliable testing that can function across both advanced urban hospitals and resource-variable settings. Japan, Australia, and South Korea combine advanced perinatal care systems with aging maternal demographics and high expectations for diagnostic precision, making PROM testing valuable within high-risk pregnancy management, preterm labor assessment, and neonatal preparedness strategies.

Actionable Recommendations for Leaders in Preterm Birth and PROM Testing

Industry leaders should prioritize clinically validated PROM testing solutions that demonstrate reliability across real-world conditions, including blood contamination, infection, variable gestational ages, and diverse patient populations. Product development should focus on rapid turnaround time, ease of use, minimal training requirements, clear result interpretation, and compatibility with obstetric triage workflows. To support adoption, healthcare stakeholders should invest in implementation evidence that links testing to meaningful outcomes such as reduced diagnostic uncertainty, optimized admissions, appropriate use of corticosteroids and antibiotics, timely referral, and reduced unnecessary interventions. Regulatory and quality strategies should be designed early, with robust analytical validation, clinical performance data, post-market surveillance, and compliance with evolving in vitro diagnostic regulations. For health systems, the priority is to embed PROM testing into standardized preterm labor and PPROM pathways rather than using tests in isolation. Training programs should reinforce correct sample collection, interpretation, documentation, and escalation steps. Partnerships with public health agencies, maternity networks, and professional societies can improve protocol adherence and equitable access. In lower-resource settings, leaders should emphasize affordability, supply stability, temperature tolerance, and decentralized usability. Across all settings, data integration with electronic medical records and AI-ready clinical datasets can create long-term value, provided privacy, consent, and bias controls are maintained.

Research Methodology for Preterm Birth and PROM Testing Analysis

This executive summary is structured around evidence-based secondary research and clinical knowledge synthesis from authoritative public health, regulatory, and medical sources. The research approach emphasizes verified information from international health agencies, national public health bodies, peer-reviewed obstetrics and gynecology literature, clinical practice guidelines, diagnostic regulatory frameworks, and maternal-newborn health policy resources. The methodology excludes market sizing, revenue estimation, market share calculation, and forecasting. Evidence was assessed for relevance to preterm birth, PROM, PPROM, diagnostic testing performance, obstetric triage, maternal-fetal outcomes, regional health system readiness, and adoption barriers. Regional, group, and country insights were developed by comparing healthcare infrastructure maturity, prenatal care access, neonatal service capacity, regulatory rigor, public health priorities, and documented maternal health disparities. The analysis also considered the operational role of diagnostics in emergency obstetric care, referral decisions, antimicrobial stewardship, and neonatal preparedness. AI-related insights were evaluated through the lens of clinical decision support, predictive analytics, data governance, and implementation safety, with emphasis on validation and bias mitigation. This methodology supports an optimized yet clinically grounded perspective for stakeholders seeking to understand the evolving role of preterm birth and PROM testing without relying on speculative commercial projections.

Conclusion: Advancing Maternal-Fetal Outcomes Through Better PROM Testing

Preterm birth and PROM testing are becoming increasingly important components of modern maternal-fetal care because they help clinicians make timely, evidence-based decisions in scenarios where diagnostic uncertainty can affect both maternal and neonatal outcomes. The strongest opportunities lie in integrating accurate PROM diagnostics into standardized triage protocols, high-risk pregnancy pathways, referral networks, and digital health systems. Regional needs differ substantially: high-income health systems are focused on precision, workflow efficiency, equity, and regulatory compliance, while resource-constrained settings require affordable, robust, and decentralized testing that supports safe referral and infection prevention. Artificial intelligence may strengthen preterm birth risk prediction and operational planning, but its value depends on validated models, representative datasets, and responsible clinical governance. For industry leaders, success will depend on clinical credibility, usability, regulatory readiness, and the ability to demonstrate practical value within real obstetric workflows. As maternal health systems continue to prioritize preventable neonatal morbidity and mortality, PROM testing will remain a critical diagnostic tool within broader strategies to improve pregnancy outcomes, optimize care delivery, and support safer births worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Preterm Birth & PROM Testing Market, by Test Category

  • 7.1. Introduction
  • 7.2. Preterm Birth Testing
  • 7.3. Premature Rupture of Membranes Testing

8. Preterm Birth & PROM Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. Immunoassay
  • 8.3. Molecular Diagnostics
  • 8.4. Imaging Technologies
  • 8.5. Sensor-Based Monitoring

9. Preterm Birth & PROM Testing Market, by Testing Mode

  • 9.1. Introduction
  • 9.2. Point-of-Care (POC) Testing
  • 9.3. Laboratory-Based Testing
  • 9.4. Continuous Monitoring Systems

10. Preterm Birth & PROM Testing Market, by Product Type

  • 10.1. Introduction
  • 10.2. Diagnostic Kits
  • 10.3. Instruments & Analyzers
  • 10.4. Consumables
  • 10.5. Software & Algorithms

11. Preterm Birth & PROM Testing Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Care
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics
  • 11.5. Research Institutes

12. Preterm Birth & PROM Testing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Preterm Birth & PROM Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Preterm Birth & PROM Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Arkray, Inc.
  • 16.3. Beckman Coulter, Inc.
  • 16.4. Becton, Dickinson and Company
  • 16.5. Bio-Rad Laboratories, Inc.
  • 16.6. Biosynex S.A.
  • 16.7. CooperSurgical, Inc.
  • 16.8. Danaher Corporation
  • 16.9. F. Hoffmann-La Roche Ltd
  • 16.10. Ferring Pharmaceuticals A/S
  • 16.11. Hologic Gen-Probe Incorporated
  • 16.12. Laborie Medical Technologies Corp.
  • 16.13. Medix Biochemica Oy
  • 16.14. Metabolomic Diagnostics Ltd
  • 16.15. NX Prenatal Diagnostics Ltd
  • 16.16. Ortho Clinical Diagnostics Holdings plc
  • 16.17. Panache HealthNeeds Pvt Ltd
  • 16.18. PerkinElmer, Inc.
  • 16.19. Progyny, Inc.
  • 16.20. QIAGEN N.V.
  • 16.21. Sera Prognostics Europe B.V.
  • 16.22. Siemens Healthineers AG
  • 16.23. Sysmex Corporation
  • 16.24. Thermo Fisher Scientific Inc.
  • 16.25. Toda Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRETERM BIRTH TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRETERM BIRTH TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRETERM BIRTH TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREMATURE RUPTURE OF MEMBRANES TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PREMATURE RUPTURE OF MEMBRANES TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREMATURE RUPTURE OF MEMBRANES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMAGING TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMAGING TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SENSOR-BASED MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SENSOR-BASED MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SENSOR-BASED MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT-OF-CARE (POC) TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT-OF-CARE (POC) TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT-OF-CARE (POC) TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LABORATORY-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTINUOUS MONITORING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTINUOUS MONITORING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTINUOUS MONITORING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSTRUMENTS & ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOFTWARE & ALGORITHMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOFTWARE & ALGORITHMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOFTWARE & ALGORITHMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 142. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 144. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. CANADA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 148. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 150. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MEXICO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 154. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 156. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. BRAZIL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED KINGDOM PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 166. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 168. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. GERMANY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 172. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 174. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. FRANCE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 178. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 180. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. RUSSIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 184. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 186. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ITALY PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 190. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 192. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. SPAIN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 202. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 204. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. INDIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 208. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 210. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 214. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 216. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. AUSTRALIA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TEST CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 220. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 222. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. SOUTH KOREA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 225. GLOBAL PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025